PTPN11 and Insulin resistance: For example, MEK inhibitors ameliorate growth defect and lean phenotype in NS-associated PTPN11 mouse model but not the insulin resistance, which is driven by a direct effect of hyperactive SHP2 on macrophages (Ptpn11D61G/+ treated with U0126) [3].